125 related articles for article (PubMed ID: 16645007)
1. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
El Fassi D; Nielsen CH; Hasselbalch HC; Hegedüs L
Eur J Endocrinol; 2006 May; 154(5):623-32. PubMed ID: 16645007
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
3. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.
El Fassi D; Clemmensen O; Nielsen CH; Silkiss RZ; Hegedüs L
J Clin Endocrinol Metab; 2007 Oct; 92(10):3762-3. PubMed ID: 17933978
[No Abstract] [Full Text] [Related]
4. B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism.
Ueki I; Abiru N; Kobayashi M; Nakahara M; Ichikawa T; Eguchi K; Nagayama Y
Clin Exp Immunol; 2011 Mar; 163(3):309-17. PubMed ID: 21235532
[TBL] [Abstract][Full Text] [Related]
5. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
6. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
Nielsen CH; El Fassi D; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
[TBL] [Abstract][Full Text] [Related]
7. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
8. B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis.
Hasselbalch HC
Immunol Lett; 2003 Jul; 88(1):85-6. PubMed ID: 12853167
[No Abstract] [Full Text] [Related]
9. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
11. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
12. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.
Resetkova E; Kawai K; Enomoto T; Arreaza G; Togun R; Foy TM; Noelle RJ; Volpé R
Thyroid; 1996 Aug; 6(4):267-73. PubMed ID: 8875745
[TBL] [Abstract][Full Text] [Related]
13. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
14. Prospects for B-cell-targeted therapy in autoimmune disease.
Edwards JC; Cambridge G
Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
[No Abstract] [Full Text] [Related]
15. Abnormal B lymphocyte function in thyroid glands from patients with Graves' disease.
Ueki Y; Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Tezuka H; Nakao H; Kawakami A; Migita K; Ishikawa
J Clin Endocrinol Metab; 1989 Nov; 69(5):939-45. PubMed ID: 2793996
[TBL] [Abstract][Full Text] [Related]
16. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
Molnár I; Balázs C
Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
[TBL] [Abstract][Full Text] [Related]
18. Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets.
Kap YS; van Driel N; Blezer E; Parren PW; Bleeker WK; Laman JD; Craigen JL; 't Hart BA
J Immunol; 2010 Oct; 185(7):3990-4003. PubMed ID: 20739677
[TBL] [Abstract][Full Text] [Related]
19. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?
Laurberg P
Eur J Endocrinol; 2006 Dec; 155(6):783-6. PubMed ID: 17132745
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.
El Fassi D; Banga JP; Gilbert JA; Padoa C; Hegedüs L; Nielsen CH
Clin Immunol; 2009 Mar; 130(3):252-8. PubMed ID: 18964302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
